[羟乙磺酸（CP-18.254）对原发性内源性高脂蛋白血症患者血脂的影响]

[Effect of tibric acid (CP-18.254) on plasma lipids in patients with primary endogenous hyperlipoproteinemia].

作者信息

Lisch H J, Sailer S, Braunsteiner H

出版信息

Arzneimittelforschung. 1977;27(10):2017-20.

Abstract

Tibric acid [CP-18.524; 2-chloro-5-(3,5-dimethyl-piperidino-sulfonyl-benzoic acid], a new hypolipidemic drug was given to 20 patients with primary endogenous hyperlipoproteinemia of type II, III, IV and V Fredrickson in a daily dose of 1.5 g for 1 year. As compared to a 4-week placebo period, the treatment with tibric acid led to a significant decrease in plasma cholesterol in 6 type-II patients (p less than 0.02) and to a significant decrease in plasma cholesterol and triglycerides in 6 type-III patients (p less than 0.001 and p less than 0.001, resp.) and in 4 type-IV patients (p less than 0.001 and p less than 0.001, resp.). No significant effect of tibric acid on plasma lipids was noted in 4 type-V patients. Apart from a moderate nausea in two patients, no side effects occurred.

摘要

安妥明丙二醇酯[CP - 18524；2 - 氯 - 5 -（3,5 - 二甲基 - 哌啶基 - 磺酰基）苯甲酸]，一种新型降血脂药物，给予20例II、III、IV和V型原发性内源性高脂蛋白血症（弗雷德里克森分型）患者，每日剂量1.5 g，持续用药1年。与4周的安慰剂治疗期相比，安妥明丙二醇酯治疗使6例II型患者的血浆胆固醇显著降低（p < 0.02），使6例III型患者的血浆胆固醇和甘油三酯显著降低（分别为p < 0.001和p < 0.001），4例IV型患者的血浆胆固醇和甘油三酯也显著降低（分别为p < 0.001和p < 0.001）。4例V型患者中未观察到安妥明丙二醇酯对血脂有显著影响。除2例患者出现中度恶心外，未发生其他副作用。